KALA BIO Inc KALA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:30 AM EDT
6.62quote price arrow up+0.11 (+1.69%)
Volume
504
52 week range
5.10 - 18.20
Loading...
  • Open6.62
  • Day High6.62
  • Day Low6.62
  • Prev Close6.51
  • 52 Week High18.20
  • 52 Week High Date06/02/23
  • 52 Week Low5.10
  • 52 Week Low Date11/14/23

Key Stats

  • Market Cap18.645M
  • Shares Out2.82M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta-1.97
  • YTD % Change-5.43

KEY STATS

  • Open6.62
  • Day High6.62
  • Day Low6.62
  • Prev Close6.51
  • 52 Week High18.20
  • 52 Week High Date06/02/23
  • 52 Week Low5.10
  • 52 Week Low Date11/14/23
  • Market Cap18.645M
  • Shares Out2.82M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta-1.97
  • YTD % Change-5.43

RATIOS/PROFITABILITY

  • EPS (TTM)-15.15
  • P/E (TTM)-0.44
  • Fwd P/E (NTM)-0.52
  • EBITDA (TTM)-39.619M
  • ROE (TTM)-262.61%
  • Revenue (TTM)-
  • Gross Margin (TTM)97.38%
  • Net Margin (TTM)-2,056.67%
  • Debt To Equity (MRQ)517.97%

EVENTS

  • Earnings Date08/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On KALA BIO Inc

 

Profile

MORE
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors...
Mark Iwicki
Chairman of the Board, Chief Executive Officer
Todd Bazemore
President, Chief Operating Officer
Mary Reumuth
Chief Financial Officer, Treasurer
Address
1167 Massachusetts Avenue
Arlington, MA
02476
United States

Top Peers

SYMBOLLASTCHG%CHG
TLPH
Talphera Inc
1.03+0.01+0.98%
SEEL
Seelos Therapeutics Inc
1.45UNCHUNCH
TXMD
TherapeuticsMD Inc
2.06-0.08-3.73%
GTBP
GT Biopharma Inc
4.57-0.45-9.06%
AVTX
Avalo Therapeutics Inc
10.74-0.04-0.42%